Neuromotor Pen

More than a pen...

NeuroMotor Pen

Product Innovation

  • Highly accurate sensor technologies built into the NeuroMotor Pen.
  • Analytical engine with Decision Support System.
  • User interface to non-invasively record and analyse parameters of minute limb and hand motion and quantify fine motor skill, represented by ‘motion features’.
  • These features are used as ‘biomarkers’ to provide objective information about movement abnormalities to support diagnosis and monitoring of Parkinson's disease and other impairments with electronic record keeping.
  • Patented and CE marked as a medical device.
  • Manufacturing setup with QMS according to all relevant standards in place.

Product Benefits

  • Triage use: for GPs to increase referral accuracy and save on costs for 50% unnecessary referrals (UK).
  • For specialists to increase certainty of differential diagnosis, especially Parkinson's versus Essential Tremor, and to monitor disease severity for improved treatment.
  • Reduced cost compared to DaTSCAN assessment.
  • Improve accuracy where there is insufficient access to skilful consultants and improve efficiency and reduce delay.
  • Patients experience a simple, non-threatening test.
  • Patient monitoring by non-specialist nurses to optimise treatment with cost reduction.
  • For academic and industrial research to support the evaluation of pharmaceutical interventions.
  • In non-neurological care settings to use as a screening tool for pre-symptomatic screening of apparently healthy individuals in groups at risk.
Full Width tablet and pen 2

Data Security

Manus Neurodynamica has implemented best-in-class encryption & cloud security technology providing:

  • Dedicated Microsoft Windows IoT with integrated Manus NMP app installation
  • A secure and locked down tablet device dedicated to NMP
  • Encryption and anonymisation of data on the tablet
  • Secure Cloud infrastructure, storage and data transport
  • Complex workflow implementation for software updates, licensing and remote device management

Manus Neurodynamica is a member of the Microsoft™ Partner program.

How the
NeuroMotor Pen™ works

How the NeuroMotor Pen™ works

How the NeuroMotor Pen™ works

The NeuroMotor Pen™ offers an accurate and objective
assessment for differential diagnosis and clinical management
of patients with neuromotor impairments, as well as
supporting drug management which can change a patient's
neuromotor functions.

The NeuroMotor Pen™ offers an accurate and objective
assessment for differential diagnosis and clinical management
of patients with neuromotor impairments, as well as
supporting drug management which can change a patient's
neuromotor functions.

The NeuroMotor Pen™ offers an accurate and objective
assessment for differential diagnosis and clinical management
of patients with neuromotor impairments, as well as
supporting drug management which can change a patient's
neuromotor functions.

How the
NeuroMotor Pen™ works

How the NeuroMotor Pen™ works

How the NeuroMotor Pen™ works

Patients complete a set of standardized NeuroMotor™ Pen handwriting and drawing tasks
with the NeuroMotor™ Pen App on a high-end tablet PC. The tasks were developed to derive as much information about the subject’s neuromotor processing with relatively few tasks.

The Pen has a wireless connection with the tablet, from where the data is sent to the cloud application, where the NeuroMotor™ Pen algorithms analyse the minute limb
and hand motion to provide the results in the App.

SmartPoints™ cybersecurity to medical standards is applied on the tablet, as well as for the data in transit and on the cloud.

Patients complete a set of standardized NeuroMotor™ Pen handwriting and drawing tasks
with the NeuroMotor™ Pen App on a high-end tablet PC.
The tasks were developed to derive as much information about the subject’s
neuromotor processing with relatively few tasks.

The Pen has a wireless connection with the tablet, from where the data is sent to the
cloud application, where the NeuroMotor™ Pen algorithms analyse the minute limb
and hand motion to provide the results in the App.

SmartPoints™ cybersecurity to medical standards is applied on the tablet,
as well as for the data in transit and on the cloud.

Patients complete a set of standardized NeuroMotor™ Pen handwriting and drawing tasks
with the NeuroMotor™ Pen App on a high-end tablet PC. The tasks were developed to derive as much information
about the subject’s neuromotor processing with relatively few tasks.

The Pen has a wireless connection with the tablet, from where the data is sent to the
cloud application, where the NeuroMotor™ Pen algorithms analyse the minute limb
and hand motion to provide the results in the App.

SmartPoints™ cybersecurity to medical standards is applied on the tablet,
as well as for the data in transit and on the cloud.

How the
NeuroMotor Pen™ works

How the NeuroMotor Pen™ works

How the NeuroMotor Pen™ works

The results of the NeuroMotor Pen™ motor skill tests are presented
as biomarkers with an easy to interpret numerical format
on the graphical user interface.

The results of the NeuroMotor Pen™ motor skill tests are presented
as biomarkers with an easy to interpret numerical format
on the graphical user interface.

The results of the NeuroMotor Pen™ motor skill tests are presented
as biomarkers with an easy to interpret numerical format
on the graphical user interface.

How the
NeuroMotor Pen™ works

How the NeuroMotor Pen™ works

How the NeuroMotor Pen™ works

The NeuroMotor™ Pen with analytical software that calculate the biomarkers can non-invasively differentiate between Parkinson’s and other disease or signs normal ageing that may mimic
the symptoms of Parkinson’s disease.

In addition to scoring biomarkers, a second level of outcome presentation
allows to categorise the results in, for example, likelihood of Parkinson’s vs Essential Tremor or other disease classification.

The NeuroMotor™ Pen with analytical software that calculate the biomarkers can non-invasively
differentiate between Parkinson’s and other disease or signs normal ageing that may mimic
the symptoms of Parkinson’s disease.

In addition to scoring biomarkers, a second level of outcome presentation
allows to categorise the results in, for example, likelihood of Parkinson’s vs Essential Tremor
or other disease classification.

The NeuroMotor™ Pen with analytical software that calculates the biomarkers can non-invasively
differentiate between Parkinson’s and other disease or signs normal ageing that may mimic
the symptoms of Parkinson’s disease.

In addition to scoring biomarkers, a second level of outcome presentation
allows to categorise the results in, for example, likelihood of Parkinson’s vs Essential Tremor
or other disease classification.

How the
NeuroMotor Pen™ works

How the NeuroMotor Pen™ works

How the NeuroMotor Pen™ works

Manus Neurodynamica provides a robust and secure
data-processing and analysis architecture including
a cloud-based facility to allow clinicians to store
the test data safely and anonymously.

Manus Neurodynamica provides a robust and secure
data-processing and analysis architecture including
a cloud-based facility to allow clinicians to store
the test data safely and anonymously.

Manus Neurodynamica provides a robust and secure
data-processing and analysis architecture including
a cloud-based facility to allow clinicians to store
the test data safely and anonymously.

previous arrow
previous arrow
next arrow
next arrow
Slider

Partners & Collaborators

smartpoints-greyscale
Partner logo cambridge cognition
Partner logo VTT
Partner logo Northumbria Healthcare
Partner logo Par Equity
Partner logo SBRI
Partner logo Stabilo
Partner logo UMCG
NeuroMotor Pen
NeuroMotor Pen
Full Width clinical data
Full Width clinician and patient 3
Full Width clinician and patient 2

Make a difference today

Our disruptive technology has the potential to be used across many applications such as screening, rehabilitation, drug development and medicine optimisation. We are keen to continue collaborating with interested researchers, clinicians and practitioners on our research in different areas of neuromotor disease, as well as investors for further development of our projects in the EU and US.